DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
HKI-357 is an investigational drug.
There have been 22 clinical trials for HKI-357. The most recent clinical trial was a Phase 3 trial, which was initiated on July 9th 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Brain Neoplasms. The leading clinical trial sponsors are Puma Biotechnology, Inc., Wyeth is now a wholly owned subsidiary of Pfizer, and NSABP Foundation Inc.
Recent Clinical Trials for HKI-357
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Puma Biotechnology, Inc.||Phase 2|
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Translational Breast Cancer Research Consortium||Phase 2|
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Dana-Farber Cancer Institute||Phase 2|